CEPI partnered with Affinivax to develop a novel COVID-19 vaccine to target variants
On Dec. 13, 2021, the Coalition for Epidemic Preparedness Innovations, and Affinivax announced a partnership to advance the…
On Dec. 13, 2021, the Coalition for Epidemic Preparedness Innovations, and Affinivax announced a partnership to advance the…
On Dec. 8, 2021, Pfizer and BioNTech announced results from an initial laboratory study demonstrating that serum antibodies…
On Dec. 8, 2021, PerkinElmer announced the research use only launch of the NEXTFLEXᆴ Variant-Seqル SARS-CoV-2 Kit v2…
On Dec. 8, 2021, Alberta announced it can track the prevalence of COVID-19 infections in nearly 75 per…
On Dec. 8, 2021, the U.S. Food and Drug Administration issued an emergency use authorization for AstraZenecaメs Evusheld…
On Dec. 7, 2021, Arbutus Biopharma, X-Chem, and Proteros announced that Arbutus had identified several molecules that inhibit…
On Dec. 7, 2021, Rockefeller University scientists announced a study had demonstrated the therapeutic potential of an unusual…
On Dec. 5, 2021, Sorrento Therapeutics announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors…
On Dec. 5, 2021, Roche announced that its planned to launch the SARS-CoV-2 & Flu A/B Rapid Antigen…
On Dec. 3, 2021, Roche and TIB Molbiol announced they had added three additional Research Use Only test…
On Dec. 1, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel detected the Omicron COVID-19 variant (B.1.1.529). To…
On Dec. 1, 2021, Fulgent Genetics confirmed that the Companyメs RT-PCR test for SARS-CoV-2, the virus that causes…
On Nov. 30, 2021, Inovio Pharma announced the company was rapidly moving to evaluate its COVID-19 DNA vaccine…
On Nov. 29, 2021, Thermo Fisher Scientific confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit…
On Nov. 29, 2021, Hologic announced that its three SARS-CoV-2 tests all detected the recently emerged Omicron variant…
On Nov. 26, 2021, Merck provided an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral…
On Nov. 26, 2021, the World Health Organization announced that the Technical Advisory Group on SARS-CoV-2 Virus Evolution…
On Nov. 23, 2021, the World Health Organization’s COVID-19 Technology Access Pool and the Medicines Patent Pool finalized…
On Nov. 22, 2021, Tonix Pharmaceuticals announced the publication of モSangivamycin is highly effective against SARS-CoV-2 in vitro…
On Nov. 19, 2021, the U.S. Food and Drug Administration (FDA) announced that it had extended the emergency…
On Nov. 18, 2021, Pfizer announced an agreement with the U.S. government to supply 10 million treatment courses…
On Nov. 16, 2021, Pfizer announced it had submitted an Emergency Use Authorization (EUA) of its investigational oral…
On Nov. 10, 2021, Meridian Bioscience announced that their Revogeneᆴ SARS-CoV-2 assay was granted Emergency Use Authorization by…
On Nov. 9, 2021, Moderna announced that it has submitted for a variation to the conditional marketing authorization…
On Nov. 9, 2021, Novan announced promising preclinical safety results with berdazimer sodium in a 14-day GLP repeat…
On Nov. 8, 2021, Cocrystal Pharma announced that its SARS-CoV-2 main protease inhibitors showed potent in vitro pan-viral…
On Nov. 5, 2021, the USDA’s (USDA) National Veterinary Services Laboratories announced confirmation of SARS-CoV-2 in two spotted…
On Nov. 5, 2021, scientists at the National Institutes of Health announced they had found that a process…
On Nov. 5, 2021, Pfizer announced it was investigational novel COVID-19 oral antiviral candidate, PAXLOVID, significantly reduced hospitalization…
On Nov. 5, 2021, Chugai Pharmaceutical, announced that it had obtained approval from the Ministry of Health, Labour…